Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

• 1 National Prescribing Service, PO Box 1147, Strawberry Hills, NSW 2012
• 2 Quality Use of Medicines, South East Health, Sydney Hospital, Sydney, NSW
• 5 Health Communication Network, St Leonards, NSW.

---

• 1. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176: 328-331. <eMJA full text>
• 2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
• 3. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283-292.
• 4. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795-806.